

**REMARKS**

As discussed below, this paper both amends the claims and responds to the restriction requirement.

**I. Claim Amendments**

This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, is presented, with an appropriate defined status identifier.

Claims 1-19 are requested to be cancelled.

Claims 20-43 are being added. Support for these claims may be found throughout the specification including the claims as originally filed. In addition, the table below lists exemplary support for the added claims.

<b>Claim(s)</b>	<b>Exemplary Support in the Application</b>
20	Original claims 2 and 4; pg. 1, l. 25; pg. 8, ll. 4-14; page 4, ll. 11-26
21	Pg. 1, l. 26; pg. 6, ll. 2-4
22	pg. 6, ll. 2-4, original claim 3
23, 24	Pg. 4, ll. 11-26; pg. 10, ll. 3-13
25	Pg. 6, ll. 2-6
26	Pg. 6, l. 21-26
27	Pg. 6, ll. 21-26
28	Original claim 6
29	Original claim 7
30	Original claim 8
31	Original claim 9
32	Original claim 10
33	Original claim 11
34	Original claim 12
35	Original claim 13
36	Original claim 14
37	Pg. 12, ll. 12-13
38	Original claim 18
39	Original claim 18, pg. 2, ll. 8-14.
40	Page 13, ll. 4-22; Example 7
41-43	Original claim 3; pg. 6, ll. 2-4; pg. 3, l. 29 – pg. 4, l. 3; pg. 7, ll. 1-8.

After amending the claims as set forth above, claims 20-55 are now pending in this application.

## **II. Restriction Requirement**

The Examiner has required restriction between the groups I-V as defined on pages 2 of the Office Action under PCT Rule 13. According to the examiner, these groups define distinct inventions.

Applicants traverse the restriction requirement as unduly excessive but file the present response merely for the sake of promptly prosecuting the case. Accordingly, Applicants elect Group I, “[c]laims 1-2, (5-12, 14, and 16, in part), drawn to an isolated polynucleotide encoding the GLP-2 receptor of SEQ ID NO: 12, said polynucleotide comprising the nucleotide sequence of set forth in SEQ ID NO: 11, a cell comprising said polynucleotide and a recombinant GLP-2 by using the cell comprising the nucleotide of SEQ ID NO: 11.” Office Action at 2.

Because claims 1-19 are canceled by this paper, Applicants respectfully request that new claims 20-43, which recite the elected subject matter, be examined.

## **CONCLUSION**

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or any other rule or provision, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date July 19, 2006

By Michele M. Simkin

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicants  
Registration No. 34,717